Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3)
- Abstract
- BACKGROUND: The efficacy of modified FOLFIRINOX (mFOLFIRINOX)as a second-line chemotherapy treatment for metastatic pancreatic adenocarcinoma (mPAC), remains unclear. This multi-center randomised phase III trial aimed to elucidate the efficacy of mFOLFIRINOX as a second-line chemotherapy treatment for mPAC patients with good performance status. PATIENTS AND METHODS: Eighty mPAC patients (age, 19-75 years) refractory to first-line gemcitabine-based chemotherapy were randomly selected to receive mFOLFIRINOX or S-1. mFOLFIRINOX comprised oxaliplatin (65mg/m(2)), irinotecan (135mg/m(2)), and leucovorin (400mg/m(2)) on day 1 and continuous 5-FU infusion (1000mg/m(2)) over 24h on days 1-2 every 2 weeks. S-1 comprised body surface area-dependent oral S-1, divided into two doses per day on days 1-28 every 6 weeks. RESULTS: Overall survival was the primary endpoint. The objective response and disease control rates were higher in the mFOLFIRINOX than in the S-1 group (15% versus 2%; p=.04 and 67% versus 37%; p=.007). The median progression-free survival rates were 5.2 and 2.2 months in the mFOLFIRINOX and S-1 groups, respectively (adjusted hazard ratio [HR]: .4; 95% confidence interval [CI]: .2-.6; p<.001). The median overall survival rates were 9.2 and 4.9 months in the mFOLFIRINOX and S-1 groups, respectively (adjusted HR: .4; 95% CI: .2-.7; p=.002). Grade 3-4 adverse events occurred in 56% and 17% of the patients in the mFOLFIRINOX and S-1 groups, respectively (p<.001). CONCLUSION: Administration of mFOLFIRINOX as a second-line chemotherapy treatment for mPAC patients refractory to gemcitabine-based chemotherapy resulted in increased survival rates than S-1 treatment alone.
- All Author(s)
- S. I. Go
; S. C. Lee
; W. K. Bae
; D. Y. Zang
; H. W. Lee
; J. S. Jang
; J. H. Ji
; J. H. Kim
; S. Park
; S. J. Sym
; Y. Yang
; S. Y. Jeon
; I. G. Hwang
; S. Y. Oh
; J. H. Kang
- Issued Date
- 2021
- Type
- Article
- Keyword
- Pancreatic neoplasms; Modified FOLFIRINOX; S-1; Second-line chemotherapy; Gemcitabine; Randomised controlled trial
- Publisher
- European Organization for Research on Treatment of Cancer
European Association for Cancer Research
- ISSN
- 0959-8049
- Citation Title
- European Journal of Cancer
- Citation Volume
- 157
- Citation Start Page
- 21
- Citation End Page
- 30
- Language(ISO)
- eng
- DOI
- 10.1016/j.ejca.2021.08.002
- URI
- http://schca-ir.schmc.ac.kr/handle/2022.oak/2628
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.